NCT01992042已完成2 期
Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Pre and post treatment effect on the Ki-67 proliferation index
研究概览
简要总结
This research study provides a novel opportunity to examine the intra-prostatic tumour inhibitory effects of statins in men with prostate cancer undergoing surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Fluvastatin/Pimonidazole
Experimental
Patients will take 40mg BID of fluvastatin. The day before surgery patients will take a single dose of pimonidazole that will be calculate based on body surface area.
干预措施: Fluvastatin (Drug)
Fluvastatin/Pimonidazole
Experimental
Patients will take 40mg BID of fluvastatin. The day before surgery patients will take a single dose of pimonidazole that will be calculate based on body surface area.
干预措施: Pimonidazole (Drug)
结局指标
主要结局
Pre and post treatment effect on the Ki-67 proliferation index
时间窗: Week 8
次要结局
- Comparison of immunohistochemical staining in Biopsy and post-RP tissues(Week 8)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Targeted Microwave Tissue Coagulation for Prostate CancerProstate CancerNCT06430749Osamu Ukimura65
终止
不适用
Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly African American Participants in a Community Outreach ProgramProstate CarcinomaNCT02419846Case Comprehensive Cancer Center319
已完成
3 期
Study of Immunotherapy to Treat Advanced Prostate CancerProstate CancerNCT00861614Bristol-Myers Squibb988
进行中（未招募）
2 期
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery EmbolizationProstate CarcinomaBenign Prostatic HyperplasiaNCT04879940H. Lee Moffitt Cancer Center and Research Institute17
进行中（未招募）
3 期
Study of Hypo-fractionated Proton Radiation for Low Risk Prostate CancerProstate CancerNCT01230866Proton Collaborative Group150